肾上腺素(Adrenaline) - 药物靶点：adrenergic receptor_在研适应症：间歇性哮喘，瞳孔散大，超敏反应_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Adrenaline (JP17)、Adrenaline Hydrochlaride、Adrenaline Hydrochloride

+ [59]

靶点

adrenergic receptor

作用方式

激动剂

作用机制

adrenergic receptor激动剂(肾上腺素能受体家族激动剂)

治疗领域

免疫系统疾病神经系统疾病心血管疾病+ [6]

在研适应症

非在研适应症

原研机构

在研机构

+ [22]

非在研机构

Shin Nippon Biomedical Laboratories, Ltd.

MannKind Corp.

G2B Pharma, Inc.

+ [3]

权益机构

Aptar France SAS

ARS Pharmaceuticals, Inc.Sandoz, Inc.

+ [15]

最高研发阶段批准上市

首次获批日期

美国 (1967-11-08),

哮喘

最高研发阶段(中国)批准上市

特殊审评快速通道 (美国)、优先审评 (美国)

登录后查看时间轴

结构/序列

分子式C9H13NO3

InChIKeyUCTWMZQNUQWSLP-VIFPVBQESA-N

CAS号51-43-4

关联

360

项与肾上腺素相关的临床试验

NCT07392580

/ Not yet recruiting临床2期IIT

A Single-Arm, Open-Label Study of Intralesional Treatment of Laryngeal Squamous Cell Carcinoma With Cisplatin

The purpose of this study is to determine the effects, good and bad, of injecting chemotherapy into recurrent laryngeal squamous cell carcinoma (SCC) tumors.

开始日期2026-04-01

申办/合作机构

University of Miami

NCT07341776

/ Recruiting临床4期IIT

Evaluation of Emergency Medication in Children With Food Allergies: a Prospective, Randomized Clinical Multicenter Study Comparing Antihistamines Versus Antihistamines Plus Steroids in a Controlled Setting of Oral Food Challenges in Children.

In this study, the investigators want to find out whether a specific medication commonly used for severe allergic reactions is really necessary. When children have allergic reactions to foods, they are often given medications to relieve the symptoms. In addition to adrenaline and antihistamines, steroids are frequently administered in German-speaking Switzerland. However, it is unclear whether steroids are really helpful in this situation. To investigate this, the investigators are comparing two groups: one group receives additional steroids, and the other does not. Which treatment a participant receives is decided randomly, like flipping a coin. The study takes place during a pre-scheduled provocation test at the clinic. If an allergic reaction occurs, the usual emergency medications will be administered. Doctors will closely monitor how the reaction develops. No additional tests or visits are required. The results of this study could help improve allergy treatment in the future.

开始日期2026-01-26

申办/合作机构

University Children's Hospital Basel

NCT07267650

/ Not yet recruitingN/AIIT

Analgesic Efficacy of iPACK Block Versus Periarticular Infiltration as an Adjunct to Femoral Triangle Block in Total Knee Arthroplasty: A Prospective, Randomized, Double-Blind, Controlled Trial

This study aims to compare two different multimodal analgesic techniques for pain management after total knee arthroplasty (TKA). The primary purpose is to determine if a combination of two specific nerve blocks administered by an anesthesiologist (Femoral Triangle Block + iPACK block) results in superior pain control compared to a combination of a nerve block and a local infiltration administered by the surgeon (FTB + Periarticular Infiltration [PAI]).
The hypothesis is that the FTB + iPACK combination will lead to a significant reduction in Numeric Rating Scale (NRS) pain scores with movement at 24 hours postoperatively.
This will be a prospective, randomized, double-blind, parallel-group, single-center study involving patients scheduled for primary unilateral TKA. Participants will be randomly assigned to one of two groups. All patients, clinicians (anesthesiologists and surgeon), and outcome assessors will be blinded to the group allocation using a double-dummy technique.

开始日期2026-01-01

申办/合作机构-

100 项与肾上腺素相关的临床结果

登录后查看更多信息

100 项与肾上腺素相关的转化医学

登录后查看更多信息

100 项与肾上腺素相关的专利（医药）

登录后查看更多信息

42,379

项与肾上腺素相关的文献（医药）

2026-03-01·JOURNAL OF PSYCHOSOMATIC RESEARCH

Postoperative visual and auditory hallucinations after cardiac surgery: VAACS umbrella study

Article

作者: Shehadeh, Majd ; Hamoudy, Kasem ; Zayed, Alaa ; Abukamleh, Ghina ; Zahran, Anwar ; Karam, Saja ; Jayouse, Batoul ; Swidan, Izzeddin ; Abu Hamdeh, Nizar ; Sawalha, Moaath ; Alhaj, Zahra'a ; Nairat, Moaath ; Altmaizee, Maya ; Ewidat, Osama ; Farah, Rahaf ; Abuirmaileh, Wajeh ; Farah, Rou'a ; Abu-Hamda, Omar ; Abdul-Hafez, Hamza A ; Sbaih, Mohammad ; Marzouqa, Bisher ; Badran, Abdalfatah ; Fraitekh, Yahya Z ; Mhesin, Deema ; Ali, Abdalkarim ; Shawer, Balqis ; Nana, Oday ; Darwazah, Ahmad ; Bali, Basem ; Othman, Wafiq ; Filho, Idiberto José Zotarelli ; Fuqha, Raya ; Abuhaniah, Lourin ; Abuzaina, Husam ; Abu-Awad, Ameen ; Dabash, Alaa ; Salous, Abdelrahman ; Mohammad, Beisan ; Shehadeh, Mustafa ; Hamdan, Yazan ; Rubi, Ala ; Bakeer, Saeed ; Abu-Alhmam, Seleen ; Al-Khdour, Issa ; Zahaika, Motasem ; Alnees, Mohammad ; Atatra, Aya ; Salah, Omar ; Alrifai, Ali ; Darwish, Abdalaziz ; Najjar, Roua ; Awwad, Mahdi ; Hazaza, Merna ; Sneineh, Omar Abu ; Jboor, Hanan ; Najajra, Duha ; Aljuba, Ayat ; Assaf, Yara ; Heih, Omar ; Ayesh, Hadeel ; Abu Khadija, Haitham ; Tamimi, Helmi ; Masu'd, Mohammad ; Jaber, Doha ; Al-Aydi, Nahi N ; Jaber, Inas ; Bali, Khalil ; Manassra, Fatima ; Abubilal, Lila ; Ismail, Sara ; Khalaf, Ro'a ; Issa, Kamal ; Yasini, Mohammad ; AbuAlrub, Ibraheem ; Alkhatib, Hasan

BACKGROUND:

Hallucinations are underrecognized neuropsychiatric complications after cardiac surgery. Data on incidence and type-specific predictors in coronary artery bypass grafting (CABG) and valvular surgery are limited.

METHODS:

We conducted a multicenter prospective cohort study (September 2022 to May 2025) across West Bank cardiac surgery centers. A total of 1332 adults (997 CABG, 335 valve) were assessed daily for 7 days postoperatively using the Questionnaire for Psychotic Experiences. Predictors of visual and auditory hallucinations evaluated with Cox proportional hazards models.

RESULTS:

Visual hallucinations occurred in 11.5 % of CABG patients and 10.0 % of valve surgery patients, while auditory hallucinations were reported in 7.0 % and 5.0 %, respectively. In the CABG group, the multivariable Cox regression models stratified by hospital showed that auditory hallucinations were significantly associated with lower left ventricular ejection fraction (HR = 1.05 per 1 % decrease; 95 % CI 1.01-1.09), longer aortic cross-clamp time (HR = 1.01 per minute; 95 % CI1.0004-1.02), and immunosuppressive therapy (HR = 4.81; 95 % CI 1.13-20.53). Postoperative blood transfusion was associated with an increased risk of visual hallucinations in univariate analysis (HR = 1.87; 95 % CI 1.05-3.33), but the association became borderline after adjustment (HR = 1.97; 95 % CI 0.95-4.09). Among the valve surgery cohort, the hospital-stratified models indicated that prolonged postoperative ventilation was independently protective against visual hallucinations (adjusted HR = 0.78; 95 % CI 0.68-0.90), whereas noradrenalin use (adjusted HR = 6.07; 95 % CI 2.18-16.93) and immunosuppressive therapy (adjusted HR = 5.13; 95 % CI 1.14-23.09) markedly increased the risk. For auditory hallucinations in valve surgery patients, adrenaline exposure emerged as a significant independent predictor (adjusted HR = 3.40; 95 % CI 1.21-9.54).

CONCLUSIONS:

Postoperative hallucinations affected ∼1 in 10 patients; visual hallucinations were more frequent, auditory hallucinations linked to stress and medications, with risks varying by surgery type, supporting tailored monitoring and prevention.

2026-03-01·Resuscitation Plus

Performing chest compressions during the initial phase of out-of-hospital cardiac arrest: continuous vs. alternating (CALM) – a study protocol for prospective, randomised, monocentric, non-blinded, mannequin study with German emergency medical service personnel

Article

作者: Neuhaus, Christopher ; Kaltschmidt, Nikolai ; Popp, Erik ; Bechtold, Johann ; Mohr, Stefan ; Weilbacher, Frank ; Kohal, Levi ; Katzenschlager, Stephan ; Klein, Marita ; Kaltschmidt, Lisa ; Hölzer, Hans Thomas ; Weigand, Markus A

Introduction:

Effective chest compressions are a core element of cardiopulmonary resuscitation (CPR). Current guidelines recommend exchanging the person performing chest compressions every two minutes to ensure high-quality chest compressions. However, this can lead to several task interruptions, which could result in a prolonged delay until other relevant tasks, such as securing the airway or administering adrenaline, are completed. Some studies have shown that a rescuer can perform sufficient CPR continuously for more than five minutes. Therefore, this study will investigate whether chest compressions without staff changes in the initial phase of CPR result in fewer task interruptions and an earlier completion of relevant tasks.

Methods and analysis:

To investigate this, a prospective, randomised, monocentric, non-blinded, mannequin study will be conducted. The 32 teams will perform CPR in two simulated settings. Each team consists of four members, according to the German emergency service standard. Before entering the scenario, they will be randomised to either CPR with or without staff changes or either a shockable or non-shockable rhythm. The scenario ends with the fourth rhythm analysis. After a 20-min break, they will enter the second scenario. Teams will be informed whether they should perform continuous or alternating CPR but will not know which rhythm they have been assigned to. The primary outcome will be the time it takes to complete all relevant tasks during the initial CPR phase. Secondary outcomes include chest compression quality, task load, and number of interrupted tasks.

Ethics and dissemination:

The protocol was approved by the ethics committee of the University of Heidelberg (S-252/2025, June 04, 2025). It is registered with the German Clinical Trials Register (DRKS00037157, June 10, 2025). Participation will be voluntary and based on informed consent. Data will be recorded only in a pseudonymised form. After completion, data will be kept on file for 10 years. The findings will be disseminated in a peer-reviewed academic journal. De-identified data from the case report form will be made publicly available within the first publication. The study will be conducted following the Declaration of Helsinki and relevant laws.

2026-03-01·ADVANCES IN PHYSIOLOGY EDUCATION

Large-scale practical cardiovascular classes with Danio rerio : overcoming ethical, financial, and logistical challenges associated with mammalian models

Article

作者: Rouse, James L. ; Seeley, Aidan ; Freestone, Nicholas S. ; Corns, Laura F.

The document outlines how large-scale undergraduate practical classes involving Danio rerio (zebrafish) can be used to teach cardiovascular physiology. It emphasizes the educational value of using live zebrafish to explore heart rate, drug effects, and homeostasis. The process supports active, inquiry-based learning, fostering engagement, critical thinking, and collaborative skills. It also addresses ethical and logistical considerations. Overall, the approach effectively combines hands-on experimental experience with core physiological concepts in an impactful educational format.

642

项与肾上腺素相关的新闻（医药）

2026-02-05

·微信

近一个月，FDA 已拒批多款新药

点击蓝字关注我们~ 2026 年以来，FDA 已拒批了多款新药，涵盖罕见病、自身免疫、眼科等领域，核心症结主要集中在有效性证据不足、安全性隐患、生产测试方法方面。　　如近日，Aquestive Therapeutics收到美国FDA发出的完整回复函(CRL)，拒绝了其肾上腺素舌下膜剂Anaphylm的新药申请。FDA此次拒绝的理由集中在“人为因素”研究的瑕疵上。在模拟过敏性休克急救场景的验证测试中，受试者在打开Anaphylm的铝箔包装袋时屡屡受挫，且部分人将药片放置在了错误的舌下位置。　　虽然在美国市场暂时受挫，但Aquestive的整体上市节奏并未打乱。公司已从欧洲药品管理局获得积极反馈，确认无需补充临床试验即可提交上市申请，预计2026年下半年进军欧洲和加拿大市场。　　2月3日，阿斯利康公告称，美国FDA就Saphnelo(阿伏利尤单抗)用于成人系统性红斑狼疮患者皮下给药的生物制品许可申请发出完整答复函(CRL)，驳回了其狼疮治疗药物的自行注射剂型上市申请。　　Saphnelo用于治疗系统性红斑狼疮，该疾病是一种自身免疫性疾病，患者的免疫系统会错误攻击自身健康组织。该药物目前已有静脉注射剂型获批上市，患者需每四周前往医院或诊所接受静脉注射治疗。此次FDA未批准的主要原因涉及药学、制造及质量控制方面的审评问题，包括制剂稳定性与生产工艺一致性等技术细节。对此，阿斯利康表示，目前仍在与监管机构沟通，推进该申请的审批进程。　　2月1日，生物制药公司Pharming Group宣布，美国FDA已正式拒绝其核心药物Joenja®(leniolisib)的补充新药申请(sNDA)。据了解，Pharming Group此次申请的核心目标，是将Joenja的适用人群拓展至4至11岁的活化磷酸肌醇3-激酶δ综合征(APDS)儿童患者。而FDA拒批的理由，主要集中在药代动力学数据与生产测试方法两大层面。　　具体来看，一方面，监管机构担忧低体重儿童患者可能出现药物暴露不足的问题。另一方面，监管机构认为该药物生产批次测试中使用的一种分析方法存在缺陷，需公司补充相关数据并作出详细说明，完成方法学验证。　　1 月 9 日，同种异体 T 细胞疗法 Ebvallo 的 BLA 申请也第二次被驳回，FDA 认为其单臂临床数据不足以支持加速批准，且试验设计、设计和数据分析方面存在问题。　　1月8日，Vanda制药公司透露，美国FDA驳回了其HETLIOZ治疗时差紊乱的申请。FDA药物评估和研究中心表示，HETLIOZ的补充新药申请(sNDA)当前形式无法获批。　　…… 　　总的来说，FDA 的集中拒批是全球医药监管从 “快速上市” 向 “安全有效并重” 的长期转型信号。未来，行业业将迎来资源向高价值领域集中、竞争向综合能力倾斜的新格局。药企需以 “临床严谨性、数据充分性、风险可控性” 为核心重塑研发体系，提升创新效率。免责声明：在任何情况下，本文中的信息或表述的意见，均不构成对任何人的投资建议。文章来源：制药网 >更多精彩： · 2026年春季药机展：参展商又有新福利 · 5个创新药纳入优先审评！ · 药企BD合作频繁终止 · 多家药企展望2026年 · 十年破壁！中国抗癌药研发突破戳“阅读原文”一起进步

细胞疗法加速审批上市批准引进/卖出

2026-02-05

·制药网

开年遇阻！近一个月FDA 已拒批多款新药

【制药网行业动态】2026 年以来，FDA 已拒批了多款新药，涵盖罕见病、自身免疫、眼科等领域，核心症结主要集中在有效性证据不足、安全性隐患、生产测试方法方面。　　如近日，Aquestive Therapeutics受到美国FDA发出的完整回复函(CRL)，拒绝了其肾上腺素舌下膜剂Anaphylm的新药申请。FDA此次拒绝的理由集中在“人为因素”研究的瑕疵上。在模拟过敏性休克急救场景的验证测试中，受试者在打开Anaphylm的铝箔包装袋时屡屡受挫，且部分人将药片放置在了错误的舌下位置。　　虽然在美国市场暂时受挫，但Aquestive的整体上市节奏并未打乱。公司已从欧洲药品管理局获得积极反馈，确认无需补充临床试验即可提交上市申请，预计2026年下半年进军欧洲和加拿大市场。　　2月3日，阿斯利康公告称，美国FDA就Saphnelo(阿伏利尤单抗)用于成人系统性红斑狼疮患者皮下给药的生物制品许可申请发出完整答复函(CRL)，驳回了其狼疮治疗药物的自行注射剂型上市申请。　　Saphnelo用于治疗系统性红斑狼疮，该疾病是一种自身免疫性疾病，患者的免疫系统会错误攻击自身健康组织。该药物目前已有静脉注射剂型获批上市，患者需每四周前往医院或诊所接受静脉注射治疗。此次FDA未批准的主要原因涉及药学、制造及质量控制方面的审评问题，包括制剂稳定性与生产工艺一致性等技术细节。对此，阿斯利康表示，目前仍在与监管机构沟通，推进该申请的审批进程。　　2月1日，生物制药公司Pharming Group宣布，美国FDA已正式拒绝其核心药物Joenja®(leniolisib)的补充新药申请(sNDA)。据了解，Pharming Group此次申请的核心目标，是将Joenja的适用人群拓展至4至11岁的活化磷酸肌醇3-激酶δ综合征(APDS)儿童患者。而FDA拒批的理由，主要集中在药代动力学数据与生产测试方法两大层面。　　具体来看，一方面，监管机构担忧低体重儿童患者可能出现药物暴露不足的问题。另一方面，监管机构认为该药物生产批次测试中使用的一种分析方法存在缺陷，需公司补充相关数据并作出详细说明，完成方法学验证。　　1 月 9 日，同种异体 T 细胞疗法 Ebvallo 的 BLA 申请也第二次被驳回，FDA 认为其单臂临床数据不足以支持加速批准，且试验设计、设计和数据分析方面存在问题。　　1月8日，Vanda制药公司透露，美国FDA驳回了其HETLIOZ治疗时差紊乱的申请。FDA药物评估和研究中心表示，HETLIOZ的补充新药申请(sNDA)当前形式无法获批。　　…… 　　总的来说，FDA 的集中拒批是全球医药监管从 “快速上市” 向 “安全有效并重” 的长期转型信号。未来，行业业将迎来资源向高价值领域集中、竞争向综合能力倾斜的新格局。药企需以 “临床严谨性、数据充分性、风险可控性” 为核心重塑研发体系，提升创新效率。　　免责声明：在任何情况下，本文中的信息或表述的意见，均不构成对任何人的投资建议。

细胞疗法上市批准加速审批引进/卖出

2026-02-03

·Pharmaceutical Technology

Aquestive receives FDA CRL for Anaphylm allergic reaction treatment

The original NDA included 11 clinical studies with approximately 967 total administrations across 411 participants. Credit: Sai Thaw Kyar / Shutterstock.com. Aquestive Therapeutics has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) regarding its new drug application (NDA) for Anaphylm, a sublingual film formulation of dibutepinephrine. The therapy aims to treat Type I allergic reactions, including anaphylaxis, in patients weighing 30kg or more. The CRL highlights deficiencies in human factors validation for Anaphylm, such as incorrect film placement and difficulty opening the pouch, which the FDA indicated could cause safety risks during anaphylaxis. Aquestive has modified the packaging and instructions for use and will conduct a new human factors validation study with these updates. The company will also address tolerability concerns in its resubmission. No concerns were raised about comparability data or chemistry, manufacturing, and controls (CMC) in the CRL. However, due to changes in human factors requirements, the FDA has requested a single pharmacokinetics (PK) study to assess any packaging or labelling modifications. The agency stated that human factors and PK studies may proceed concurrently. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Aquestive intends to request a Type A meeting with the FDA to review options for resubmission and expects to file its NDA again in the third quarter of 2026, following the completion of required studies. The company continues regulatory activities for Anaphylm in Europe, the UK, and Canada. Positive feedback from European regulators means no additional clinical trials are currently required before submitting applications. The original NDA included 11 clinical studies with nearly 967 total administrations across 411 participants. Aquestive Therapeutics president and CEO Daniel Barber said: “We are encouraged that the issues in the letter are limited to human factors and a supportive PK study, once human factors are addressed, and we noted several labelling comments that will inform the final label for Anaphylm, if approved by the FDA. “We remain confident in the effectiveness and safety of Anaphylm and its potential as an easy-to-use, easy-to-carry, fast-acting epinephrine treatment. We look forward to working with the FDA to achieve approval for Anaphylm.” In August 2025, Aquestive made a strategic funding agreement worth $75m with RTW Investments to support the potential launch of Anaphylm.

申请上市

100 项与肾上腺素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00095	肾上腺素	C01CA24 B02BC09 S01EA01	DB00668

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
间歇性哮喘	美国	Armstrong Pharmaceuticals, Inc.	2018-11-07
瞳孔散大	美国	Ph Healthcare Services	2012-12-07
超敏反应	美国	Viatris Specialty LLC	1987-12-22
麻醉	日本	Daiichi Sankyo Co., Ltd.	1986-02-25
支气管痉挛	日本	Daiichi Sankyo Co., Ltd.	1986-02-25
出血	日本	Daiichi Sankyo Co., Ltd.	1986-02-25
低血压	日本	Daiichi Sankyo Co., Ltd.	1986-02-25
休克	日本	Daiichi Sankyo Co., Ltd.	1986-02-25
过敏反应	中国	远大医药集团	1981-01-01
心脏停搏	中国	远大医药集团	1981-01-01
哮喘	美国	Wyeth Consumer Healthcare LLC	1967-11-08

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
过敏性鼻炎	临床2期	加拿大	Nasus Pharma Ltd.	2025-11-03
季节性过敏性鼻炎	临床2期	加拿大	Nasus Pharma Ltd.	2025-11-03
持续性哮喘	临床2期	美国	ARS Pharmaceuticals, Inc.	2022-07-28
荨麻疹	临床2期	美国	ARS Pharmaceuticals Operations, Inc.	2022-07-28
速发型超敏反应	临床2期	加拿大	Aquestive Therapeutics, Inc.	2022-07-12
药物过敏反应	临床1期	瑞典	Orexo AB	2024-04-22
呼吸道感染	临床1期	澳大利亚	ARS Pharmaceuticals, Inc.	2021-08-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04032119 (Pubmed \| Gastrointest Endosc)	临床3期	胃粘膜病变	774	1:100,000 diluted epinephrine-added injection solution	範遞範襯壓範醖鹹獵觸(鬱簾壓憲襯鹹醖艱膚憲) = 製膚膚壓鑰襯顧網範淵製範夢醖餘鏇鏇夢繭鬱 (鹹鹽範淵積構衊餘鑰壓, 46.0)	积极	2026-01-01
				Normal injection solution	範遞範襯壓範醖鹹獵觸(鬱簾壓憲襯鹹醖艱膚憲) = 窪鬱窪獵鏇鏇襯獵鏇簾製範夢醖餘鏇鏇夢繭鬱 (鹹鹽範淵積構衊餘鑰壓, 45.0)
NCT02722746 (Pilot epinephrine dose-finding study, CTgov)	临床1/2期	镇痛 \| 低血压	66	Ropivacaine (Ropivacaine Only Control Group)	廠壓顧夢憲衊醖製願齋: percent difference = 20.8 (95% CI, -8.9 ~ 47.3), P-Value = 0.165	-	2025-06-18
				Ropivacaine+Epinephrine (Ropivacaine + 2 mcg/mL Epinephrine)
CTIS2024-514037-38-00 (OX640-002, Company_Website) 人工标引	N/A	过敏性鼻炎	30	OX640	網壓製廠獵鏇鹹簾鑰糧(衊廠憲衊積齋範糧鏇鑰) = Topline data analysis demonstrates that OX640 treatments achieved mean epinephrine plasma levels associated with clinical efficacy more rapidly than the intramuscular injection, with dose-dependent exposure levels. 選糧網衊鹽簾願壓築衊 (醖膚鬱鹽觸膚選憲遞醖 ) 更多	积极	2025-01-10
				0.3 mg intramuscular epinephrine
GlobeNewswire 人工标引	N/A	口腔过敏综合征	-	Anaphylm (with allergen exposure)	鬱餘鹽構糧艱願構鏇築(觸艱鑰窪選選艱範選壓) = no significant differences found between Anaphylm PK results in subjects with and without allergen exposure. 遞遞衊齋選淵積窪網鑰 (遞鬱積衊鹹憲鏇壓艱築 ) 达到更多	积极	2024-10-24
				Anaphylm (without allergen exposure)
NCT04207840 (Pubmed \| J Aerosol Med Pulm Drug Deliv)	临床4期	哮喘 \| 过敏反应	28	Epinephrine MDI	糧獵襯獵鑰蓋繭夢糧夢(窪膚製鑰鑰鬱鑰蓋壓齋) = 願觸繭範範選艱淵鏇觸製範憲顧壓範膚鏇憲鹹 (構鑰鑰鬱壓淵築獵範鑰 )	积极	2024-08-29
				Epinephrine IM	糧獵襯獵鑰蓋繭夢糧夢(窪膚製鑰鑰鬱鑰蓋壓齋) = 繭壓鏇膚願鏇遞顧廠獵製範憲顧壓範膚鏇憲鹹 (構鑰鑰鬱壓淵築獵範鑰 )
NCT03126968 (PROPHET, CTgov)	临床2/3期	出血 \| 肺移植排斥反应 \| 咯血	66	Topical epinephrine (Prophylactic Topical Epinephrine)	憲網選衊醖廠簾醖願簾 = 鹽鬱顧繭範齋艱鹽鏇鹹簾範廠鏇衊糧鏇艱窪襯 (膚選網獵構築顧壓築鏇, 遞獵築顧鹽鏇繭鹹鬱膚 ~ 鏇鹹夢遞築簾網鬱繭淵) 更多	-	2024-08-28
				Placebos (Placebo)	憲網選衊醖廠簾醖願簾 = 鹽糧觸窪簾鏇製襯獵簾簾範廠鏇衊糧鏇艱窪襯 (膚選網獵構築顧壓築鏇, 窪膚壓鑰遞網襯簾壓選 ~ 鏇簾願鑰憲顧願製淵選) 更多
GlobeNewswire 人工标引	N/A	超敏反应	36	Anaphylm™ (epinephrine) Sublingual Film	壓獵鹽蓋餘選窪鹹鏇鏇(廠壓獵蓋膚構廠構觸廠) = 鬱鏇壓網艱廠蓋鏇鹹膚範蓋膚顧鹽積觸構範襯 (淵壓憲積鏇夢網醖選鑰 ) 达到	积极	2024-07-25
				Adrenalin manual intramuscular (IM) injection	壓獵鹽蓋餘選窪鹹鏇鏇(廠壓獵蓋膚構廠構觸廠) = 獵顧選遞願糧選鹹鹹製範蓋膚顧鹽積觸構範襯 (淵壓憲積鏇夢網醖選鑰 ) 达到
NCT05881915 (MD-245-2022, Pubmed)	N/A	低血压	98	Epinephrine infusion (0.03 mcg/kg/min)	願鹽網繭遞餘獵製淵製(糧淵衊鏇鏇齋蓋遞鹽齋) = 積艱鏇遞廠廠衊願夢醖壓襯齋網鹽願淵醖願網 (艱築積繭鑰網壓憲積齋 )	积极	2024-05-25
				Phenylephrine infusion (0.4 mcg/kg/min)	願鹽網繭遞餘獵製淵製(糧淵衊鏇鏇齋蓋遞鹽齋) = 繭觸蓋夢顧鑰廠簾膚網壓襯齋網鹽願淵醖願網 (艱築積繭鑰網壓憲積齋 )
GlobeNewswire 人工标引	临床3期	超敏反应	100	Anaphylm (single dosing part)	鹽獵艱遞選獵餘壓繭範(齋願觸糧獵築築製艱憲) = 顧襯齋蓋鏇蓋餘製襯鹽鹽獵鑰鏇網壓範範餘餘 (繭願築網鏇鬱餘鹹觸餘 ) 更多	积极	2024-03-14
				Anaphylm (repeat dosing part)	繭願築艱鬱選艱選繭構(願窪築齋鹹衊鬱獵積壓) = 獵範襯淵遞淵網憲壓夢構顧鏇壓鬱簾窪鏇顧糧 (鏇積餘窪選簾艱鏇蓋廠 ) 更多
JPRN-jRCT2031230143 (AAAAI 12024 \| AAAAI 22024) 人工标引	临床3期	超敏反应 \| 过敏反应	15	neffy 1.0mg	獵鬱願鏇鹹廠願遞襯顧(築壓鬱蓋繭顧鑰蓋鹹網) = 構鏇簾糧製齋鏇遞鏇遞積選願遞製淵觸網築餘 (遞壓獵艱鏇顧構艱簾膚 ) 更多	积极	2024-02-24
				neffy 2.0mg	獵鬱願鏇鹹廠願遞襯顧(築壓鬱蓋繭顧鑰蓋鹹網) = 壓鬱淵膚願衊製築鹽簾積選願遞製淵觸網築餘 (遞壓獵艱鏇顧構艱簾膚 ) 更多